


# Associations of Local Cannabis Control Policies With Harmful Cannabis Exposures Reported to the California Poison Control System

 Ellicott C. Matthay<sup>a</sup> Leyla M. Mousli,<sup>b</sup> Chloe Sun,<sup>b</sup> Justin Lewis,<sup>c</sup> Laurie M. Jacobs,<sup>b</sup> Stuart Heard,<sup>c</sup> Raymond Ho,<sup>c</sup> Laura A. Schmidt,<sup>b,d</sup> and Dorie E. Apollonio<sup>e</sup>

**Background:** Cannabis exposures reported to the California Poison Control System increased following the initiation of recreational cannabis sales on 1 January 2018 (i.e., “commercialization”). We evaluated whether local cannabis control policies adopted by 2021 were associated with shifts in harmful cannabis exposures.

**Methods:** Using cannabis control policies collected for all 539 California cities and counties in 2020–2021, we applied a differences-in-differences design with negative binomial regression to test the association of policies with harmful cannabis exposures reported to California Poison Control System (2011–2020), before and after commercialization. We considered three policy categories: bans on storefront recreational retail cannabis businesses, overall restrictiveness, and specific recommended provisions (restricting product types

or potency, packaging and labeling restrictions, and server training requirements).

**Results:** Localities that ultimately banned storefront recreational retail cannabis businesses had fewer harmful cannabis exposures for children aged <13 years (rate ratio = 0.82; 95% confidence interval = 0.65, 1.02), but not for people aged >13 years (rate ratio = 0.97; 95% confidence interval = 0.85, 1.11). Of 167 localities ultimately permitting recreational cannabis sales, overall restrictiveness was not associated with harmful cannabis exposures among children aged <13 years, but for people aged >13 years, a 1-standard deviation increase in ultimate restrictiveness was associated with fewer harmful cannabis exposures (rate ratio = 0.93; 95% confidence interval = 0.86, 1.01). For recommended provisions, estimates were generally too imprecise to detect associations with harmful cannabis exposures.

**Conclusion:** Bans on storefront retail and other restrictive approaches to regulating recreational cannabis may be associated with fewer harmful cannabis exposures for some age groups following statewide commercialization.

**Keywords:** Cannabis; California; Local government; Marijuana; Poison Control; Policy

(*Epidemiology* 2024;35: 447–457)

Submitted July 19, 2023; accepted March 18, 2024

From the <sup>a</sup>Center for Opioid Epidemiology and Policy, Division of Epidemiology, Department of Population Health, New York University Grossman School of Medicine, New York, NY; <sup>b</sup>Philip R. Lee Institute for Health Policy Studies, School of Medicine, University of California, San Francisco, San Francisco, CA; <sup>c</sup>California Poison Control System, School of Pharmacy, University of California, San Francisco, San Francisco, CA; <sup>d</sup>Department of Humanities and Social Sciences, School of Medicine, University of California, San Francisco, San Francisco, CA; and <sup>e</sup>School of Pharmacy, University of California, San Francisco, San Francisco, CA.

This work was supported by grants K99/R00 AA028256 from the National Institute on Alcohol Abuse and Alcoholism, C21CR2029 from the University of California Office of the President Cancer Research Coordinating Committee, RG-1603070583-553 from the California Bureau of Cannabis Control, R21 DA046051 from the National Institute on Drug Abuse, and R01 CA268491 from the National Cancer Institute. This work is solely the responsibility of the authors and does not necessarily represent the official views of the funders.

**Disclosure:** The authors report no conflicts of interest.

Statistical code used to clean and analyze the data are available in the supplemental digital content. The analytic data from the California Poison Control System are not available externally.

**SDC** Supplemental digital content is available through direct URL citations in the HTML and PDF versions of this article ([www.epidem.com](http://www.epidem.com)).

Correspondence: Ellicott C. Matthay, Department of Population Health, NYU Grossman School of Medicine, 180 Madison Ave, New York, NY 10016. E-mail: [ellicott.matthay@nyulangone.org](mailto:ellicott.matthay@nyulangone.org).

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

ISSN: 1531-5487/24/354-447457

DOI: 10.1097/EDE.0000000000001737

in Poison Control records. Adults who intentionally consume a recommended dose of a cannabis product may experience adverse effects such as vomiting or psychotic symptoms.<sup>9,14</sup> Consumers may also intentionally overdose, defined by poison centers as purposeful exposure to nonstandard doses of tetrahydrocannabinol-containing products with the intent to gain a high, euphoria, or some other psychotropic effect.<sup>15</sup> Unintentional overdoses may arise from unfamiliarity with new product types (e.g., concentrates), confusion about dosing, or lack of guidance on safe consumption.<sup>16</sup> Acute cannabis overdoses may manifest as vomiting, ataxia, disorientation, psychotic symptoms, or psychological distress.<sup>9,14,17,18</sup> Cannabis can be mistaken for other products and consumed unintentionally, particularly by children.<sup>19–27</sup> Finally, like most products, cannabis can be spoiled or contaminated with other drugs or chemicals.

Research has documented increases in cannabis-related calls to Poison Control centers following cannabis legalization and commercialization.<sup>19–22</sup> In California, cannabis-related calls to Poison Control centers increased by 64% following recreational legalization (November 2016) and an additional 29% following the initiation of recreational retail sales (“commercialization,” January 2018) (Box), particularly among children aged 12 years and under and for edible products.<sup>20</sup> Existing studies have focused on state-level patterns, but states can devolve regulatory powers over cannabis to the local level.<sup>28–32</sup> In California, cities and counties can determine retail tax rates, limit outlet densities or locations, regulate the types and potency of products sold, establish packaging and labeling requirements beyond state requirements, and mandate whether salespeople need to be trained to advise customers on dosing (e.g., “budtender training”), among others. This local policy variation provides a unique opportunity to compare alternative regulatory strategies and potentially identify effective prevention approaches.

We evaluated whether local cannabis control policies adopted following statewide recreational cannabis commercialization may help prevent increases in harmful cannabis exposures reported to Poison Control. We focus on California, which has the largest legal cannabis market worldwide (\$6 billion in annual sales)<sup>33,34</sup> and a comparatively high degree of local autonomy in regulating cannabis. We hypothesized that localities that adopted more restrictive regulatory approaches would experience smaller increases in harmful cannabis exposures following commercialization.

## METHODS

### Policy Data Collection and Measures

The cannabis policy data collection and coding are described in detail elsewhere.<sup>31,35,36</sup> The complete protocol and data collection instrument are provided in eAppendices 1–2; <http://links.lww.com/EDE/C129>. Briefly, we measured local cannabis control policies for California’s 58 counties and all

### BOX. KEY EVENTS IN CALIFORNIA STATE CANNABIS HISTORY

Medical cannabis legalization (1996): Medical cannabis was legalized on 5 November 1996, with the passage of Proposition 215, the Compassionate Use Act. The law permitted the use, possession, and cultivation of cannabis by patients with a physician’s recommendation for the treatment of a qualifying medical condition. Dispensaries selling medical cannabis were subsequently introduced. Many medical cannabis dispensaries, both licensed and unlicensed, were operating at the time that recreational cannabis was legalized.

Recreational cannabis legalization (“Legalization”) (2016): Recreational cannabis was legalized on 8 November 2016, with the passage of Proposition 64, the Adult Use of Marijuana Act. The law legalized the possession, use, and personal cultivation of recreational cannabis in California for adults aged 21 years and older. Licenses to cultivate, transport, manufacture, test, or sell recreational cannabis did not become active until 2018.

Initiation of recreational cannabis retail sales (“Commercialization”) (2018): Legal sales of recreational cannabis to adults aged 21 years and older through retail outlets began on 1 January 2018. Cities and counties reserved the option to ban recreational retail cannabis business from siting within their borders, but receipt of home delivery of retail cannabis was permitted statewide beginning in November 2018. Thus, in cities and counties that did not ban retail cannabis businesses, legal retail sales of recreational cannabis became available through storefronts in January 2018 and home delivery in November 2018, whereas in cities and counties that did ban retail cannabis businesses, legal retail sales of recreational cannabis became available only through home delivery in November 2018. Sales occurred through retail outlets that were formerly or concurrently licensed for medical cannabis or through newly opened recreational retail outlets.

482 incorporated cities within them. Incorporated city policies apply within city borders, and county policies apply to areas outside of incorporated cities (“unincorporated county areas”). The combined set of 539 incorporated cities and unincorporated county areas were the mutually exclusive and collectively exhaustive jurisdictions (“localities”) to which distinct policies applied.

Following established legal epidemiology procedures,<sup>37,38</sup> we systematically collected and coded characteristics of local cannabis control policies. We used a structured data collection instrument to capture the presence or absence and content of prespecified provisions. Localities were coded independently by two analysts until achieving >95% agreement with interpretations confirmed by a legal expert. Policy

Downloaded from http://journals.lww.com/epidem by BhDMf5ePHkav1ZEum1tQIN4a+kULnEZqshHd4XM0hCQwCX1  
AMN7Qp/llQ#HD33D00Ry7TVSF4C3VC1y0abg9QZXdG5j2MwizLEl= on 10/01/2024

TABLE 1. California Local Cannabis Control Policy Measures Adopted by 2021

Policy Measure	Description	Summary Statistic(s)
Bans on storefront recreational retail cannabis businesses	The state permits commercial businesses for the retail sale of recreational cannabis with a state-issued license. However, localities can ban retail cannabis businesses from siting within the locality's borders. We focused on local bans on businesses selling recreational cannabis instead of medical cannabis because our study covers the postrecreational legalization period. <sup>a</sup> We focused on storefront (brick-and-mortar) businesses as opposed to home delivery retailers, because receipt of home delivery was legal statewide, versus physical proximity to outlets offering in-person purchases. <sup>40</sup>	Localities banning storefront recreational retail businesses by 2021: 69% Median (minimum, maximum): 7 (1, 13) <sup>b</sup>
Overall restrictiveness of cannabis control policies	We created a policy score capturing overall restrictiveness by summing the 18 binary policy variables relevant to the operations of retail outlets and availability of retail recreational cannabis: bans on on-site consumption, outlet density limits, outlet location limits, bans on outlet overconcentration in vulnerable communities, restrictions on outlet locations in relation to alcohol outlets, limits on hours or days of sale, outlet buffers around sensitive locations such as schools, buffers between outlets, requirements for outlet upkeep, requirements for outlet safety (e.g., night lighting), limits on advertising and marketing, liability for hosting underage consumption (social host), restrictions on special outdoor events involving cannabis, limits on product types or potency, restrictions on packaging and labeling, server training requirements, taxes on retail purchases, and other price controls. This list includes all cannabis control policy measures we collected except those pertaining to bans on cannabis cultivation, manufacture, distribution, or testing businesses.	
Specific provisions		
Limits on product types and potency	Applicable local policies include bans on specific product types such as cannabis-infused beverages or flavored combustibles, or maximum allowable tetrahydrocannabinol potency levels of products.	Localities adopting any limits by 2021: 7% <sup>b</sup>
Requirements for product packaging or labeling	Applicable local policies include supplemental warning labels (beyond those required by state law) and requirements of plain packaging (e.g., no depictions of persons, characters, or animals). State law mandates that cannabis products cannot be attractive to children and should not be easily confused with non-cannabis-containing commercially available foods. Local policies in this category also include heightened standards for what qualifies as attractive to children or appearing like a non-cannabis-containing product.	Localities adopting any requirements by 2021: 13% <sup>b</sup>
Server training requirements	Applicable local policies include mandatory or voluntary "budtender" training requirements for retail licensees, managers, servers, or other employees of retail businesses. The content of the training may include advising customers on recommended dosing or procedures for preventing sale to intoxicated persons or minors. Training may be provided by the local government, the permittee, or a third party.	Localities adopting any requirements by 2021: 3% <sup>b</sup>

<sup>a</sup>Receipt of cannabis home delivery is legal statewide, but localities can ban businesses offering delivery from siting within their borders.

<sup>b</sup>Values are reported for the subset of localities that permit recreational retail cannabis businesses.

data collection was conducted from November 2020 to August 2021.

The local policies we measured were based on an existing taxonomy of all possible cannabis policies developed through literature review and expert discussion.<sup>39</sup> We coded all major categories of policies that (1) could be adopted by city or county governments according to state law, (2) were more restrictive than state law, (3) varied across localities, and (4) were plausibly related to public health, based on existing evidence, public health best practices, and expert opinion.<sup>28,29,39</sup>

In this study, we evaluated three categories of local cannabis control policy measures (Table 1). First, we examined bans on storefront retail businesses selling recreational cannabis (hereafter, “retail bans”). Second, we generated a policy score capturing the overall restrictiveness of a locality’s cannabis control policies by summing the 18 binary policy variables relevant to the operations of retailers and the availability of recreational retail cannabis. Third, we considered specific provisions recommended as potential solutions to harmful cannabis exposures identified by Poison Control:<sup>9</sup> limits on product types and potency, packaging and labeling requirements, and server training requirements.<sup>9</sup> While some other policies are more common (e.g., retail taxes), these three policies address explicit mechanisms leading to overdoses (e.g., consumer confusion about dosing). We examined the restrictiveness score and specific provisions for the subset of localities without retail bans. For all three categories, the exposures were cross-sectional measures of the policies applicable at the time of data collection. Because statewide commercialization preceded data collection, we interpret our estimates as patterns in harmful cannabis exposures in localities that did versus did not adopt the given policy by 2021. To assess whether the measured policies were effective throughout the postcommercialization period 2018–2021, we retrospectively evaluated a random sample of 20 localities. We found that 50% had unchanged policies throughout 2018–2021, 15% made minor changes (e.g., clarifying a definition), and 35% made major changes. See eAppendix 3; <http://links.lww.com/EDE/C129> for details.

### California Poison Control System (CPCS) Data

We used data collected by California Poison Control System (CPCS), a network of four call-answering sites. CPCS maintains a free 24/7 hotline providing expert advice on exposure management to the lay public and medical practitioners. We analyzed all CPCS calls from 1 January 2011 to 31 December 2020 originating from California and involving human exposure to “marijuana” (ingested, inhaled, absorbed, or applied to the body), based on product codes used by all accredited US Poison Control centers to identify cannabis-containing products. Call records included patient demographics, caller location, substance, route of exposure, symptoms, treatment, and medical outcomes. The Institutional Review

Board of the University of California, San Francisco approved this study.

Medical outcomes (hereafter, “severity”) were categorized following Poison Control standards into no effect, minor, moderate, and severe.<sup>15</sup> Examples of minor effects included self-limited gastrointestinal illness; moderate effects included pronounced or systemic symptoms typically requiring treatment (e.g., psychosis); severe effects were life-threatening (e.g., respiratory compromise requiring intubation) or death. In the primary analysis, we excluded cases with no effect (e.g., informational calls), instead focusing on harmful cannabis exposures, defined as those involving minor, moderate, or severe medical outcomes. We aggregated individual call record data to the locality–quarter level. The primary outcome was the rate of harmful cannabis exposures reported to CPCS using census-based denominators. Additional detail on outcome classification and data cleaning procedures is provided in eAppendix 3; <http://links.lww.com/EDE/C129>.

### Statistical Analysis

We merged the local cannabis policy data to CPCS outcomes by locality. Of the original 539 localities, we excluded four for which no legal text could be identified and four that did not specify whether recreational retail cannabis businesses were permitted. The final analytic dataset included a balanced panel of 531 localities over 40 quarters.

To estimate the associations of the local cannabis control policies adopted by 2021 with harmful cannabis exposures before and after commercialization, we applied a two-way fixed effects design,<sup>41</sup> a generalization of differences-in-differences for the setting with multiple treated units. Our modeling approach was based on a simulation study that compared the performance (bias, precision) of common approaches for estimating policy effects in panel data.<sup>42</sup> The authors found that the optimal method was a negative binomial model that included an autoregressive effect.<sup>42</sup> However, some locality–quarters had no harmful cannabis exposures, so incorporating autoregressive terms would have involved  $\log(0)$ . We, therefore, employed the next-best approach identified by the study and used negative binomial regression to model the rate of harmful cannabis exposures as a function of the policy variables, locality fixed effects, and quarter fixed effects with standard errors clustered at the locality level (see eAppendix 3; <http://links.lww.com/EDE/C129> for statistical model). The locality fixed effects controlled for time-invariant characteristics of localities (e.g., political orientation, population density, and wealth) and the quarter fixed effects controlled for temporal patterns that were universal across localities (e.g., statewide legalization and trends in cannabis product potency) that would otherwise confound the results. Remaining potential confounders are time-varying, locality-specific factors that relate to (1) which local cannabis policies were adopted and (2) rates of reported harmful cannabis exposures. Additionally, our



approach relies on the assumption of parallel trends on the multiplicative scale.<sup>43</sup> That is, we assume that the trends in the log-transformed outcome rates in the localities that did not adopt the given policy are parallel to the trends in the outcomes in the localities that did adopt the policy, had these localities (counter-to-fact) not adopted the policy (see eAppendix 3; <http://links.lww.com/EDE/C129> for detail). We are not aware of any concurrent changes that affected harmful cannabis exposures, supporting the plausibility of this assumption, but we cannot rule out uncontrolled confounding. Under the assumptions of parallel trends and no anticipation, the exponentiated coefficient on the policy exposure variable is the standard differences-in-differences estimate of the average treatment effect on the treated (in this case, an associational rate ratio [RR]).<sup>41</sup>

All analyses were stratified by age group (under 13 years vs. 13 years and older), because prior research indicated differential impacts of statewide recreational cannabis commercialization between these two age groups<sup>20</sup> and because exposures for the younger age group were frequently unintentional consumption of edibles whereas exposures among older age group were more often intentional and varied in product type.<sup>20</sup> We fit separate models for each category of policy measures: first, retail bans, among all localities; second, overall restrictiveness, among localities without retail bans; and third, the three specific provisions plus a new restrictiveness score made up of the remaining 15 cannabis control policies (without the three specific provisions), among localities without retail bans. For analyses involving overall policy restrictiveness, we standardized the policy score so that estimates correspond to the change in the rate of harmful cannabis exposures associated with a 1-standard deviation increase in the policy restrictiveness score, a substantial increase in restrictiveness (see eFigure 1; <http://links.lww.com/EDE/C129>).

In subgroup analyses, we stratified the outcome by patient gender (men, women), mode of cannabis product consumption (ingested, inhaled), medical outcome severity (minor, moderate, major/death), and caller site (community, health care facility). To test the robustness of our results to our specification choices, we conducted sensitivity analyses in which we (1) restricted to exposures involving cannabis but no other substances and (2) included cases of unknown severity (see eAppendix 3; <http://links.lww.com/EDE/C129>). Consistent with increasing concerns about the value of null hypothesis significance testing, we do not adjust for multiple comparisons.<sup>44,45</sup> All analyses were performed in R version 4.3.0, The R Foundation for Statistical Computing, Vienna, Austria (see eAppendix 4; <http://links.lww.com/EDE/C129> for code).

## RESULTS

Of 539 localities, we obtained the cannabis control policy text for 535 (99%). Of these, 69% had retail bans (Table 1). Among the 167 localities without retail bans, the median cannabis policy restrictiveness score was 7 (range: 1–13). Only

7% of localities placed any type of limit on product types or potency, 13% adopted any requirements for product packaging and labeling beyond state laws, and 3% placed some form of server training requirement.

There were 7906 harmful cannabis exposures reported to CPCS over the study period, and we linked 7,668 (97%) to their originating locality (Table 2). Among the cases, 55% were men, 76% were people aged 13 years or older, 59% involved cannabis only (vs. cannabis and other substances), 80% involved ingestion (vs. inhalation or another route of exposure), 71% were minor severity, and 66% were calls made from health care facilities. Reported exposures increased over time from 565 in 2011 to 1,343 in 2020.

In adjusted analyses (Figure 1), localities that adopted bans on storefront recreational retail cannabis businesses by 2021 had 18% fewer harmful cannabis exposures for people aged 12 years and under compared to localities not adopting such bans by 2021 (RR = 0.82; 95% confidence interval [CI] = 0.65, 1.02). However, we observed no association for people aged 13 years and older (RR = 0.97; 95% CI = 0.85, 1.11). For people aged 12 years and under, this RR corresponds to approximately 10 cases averted annually (2018–2020) among all localities adopting retail bans by 2021 combined. Subgroup analyses revealed that the reduction in harmful cannabis exposures for those <13 years applied primarily to moderate severity cases (RR = 0.37; 95% CI = 0.22, 0.64), ingested products (RR = 0.80; 95% CI = 0.64, 1.01), and calls originating from health care facilities (RR = 0.74; 95% CI = 0.57, 0.96). In subgroup analyses for ages 13 and older, associations with retail bans were generally null. One exception was that retail bans were associated with lower rates of high-severity cannabis exposures, but this estimate was imprecise (RR = 0.72; 95% CI = 0.45, 1.15).


In adjusted regression analyses restricted to the 167 localities without retail bans by 2021 (Figure 2), the overall restrictiveness of a locality's cannabis control policies in 2021 was not associated with changes in harmful cannabis exposures among children aged 12 years and under, overall or for any subgroup. For people aged 13 years and older, localities with a 1-standard deviation higher level of overall restrictiveness experienced 7% fewer harmful cannabis exposures for people aged 13 years and older compared with less restrictive localities (RR = 0.93; 95% CI = 0.86, 1.01), corresponding to approximately 11 cases averted annually among all localities adopting more restrictive approaches to cannabis control by 2021. This finding was driven by medium-severity cases (RR = 0.82; 95% CI = 0.71, 0.94) and calls originating from health care facilities (RR = 0.89; 95% CI = 0.80, 0.98).

For limits on product types or potency, packaging and labeling requirements, and server training requirements, we generally did not detect differences in rates of harmful cannabis exposures between localities with and without these policies by 2021 (eFigures 2–4; <http://links.lww.com/EDE/C129>). Fewer than 15% of localities adopted these policies (Table 1)

Downloaded from http://journals.lww.com/epidem by BhDMf5ePHKav1zEoum1tQIN4a+kULNEZgbsH0dXMI0hCQwCX1  
AWN7YQp/IIQHD33D00dR7/TVSFH4C3VC1y0abggQZXdG5j2MwizLeI= on 10/01/2024

TABLE 2. Characteristics of Harmful Cannabis Exposures Reported to the California Poison Control System, 2011–2020, Overall and by Locality Stance on Storefront Recreational Retail Cannabis Businesses in 2021

Characteristic	Overall		Localities Banning Storefront Recreational Retail Cannabis by 2021 (n = 368 [69%])		Localities Permitting Storefront Recreational Retail Cannabis by 2021 (n = 167 [31%])	
	n	%	n	%	n	%
Exposures	7,668	100%	3,785	100%	3,869	100%
Gender						
Woman	3,460	45%	1,646	43%	1,809	47%
Man	4,208	55%	2,044	54%	2,123	55%
Age						
Under 13 years	1,821	24%	835	22%	983	25%
13 years or older	5,847	76%	2,950	78%	2,886	75%
Number of substances involved						
Cannabis only	4,566	59%	2,163	57%	2,396	62%
Cannabis and other(s)	3,102	41%	1,622	43%	1,473	38%
Route of exposure						
Ingested	6,130	80%	3,020	80%	3,097	80%
Inhaled	1,243	16%	630	17%	613	16%
Other	295	4%	135	4%	59	4%
Medical outcome severity						
Minor	5,452	71%	2,696	71%	2,746	71%
Moderate	1,915	25%	928	25%	983	25%
Severe (major or death)	301	4%	161	4%	140	4%
Call site						
Health care facility	5,080	66%	2,638	70%	2,430	63%
Community	2,588	34%	1,146	30%	1,438	37%
Year						
2011	565	7%	274	7%	290	7%
2012	486	6%	236	6%	250	6%
2013	441	6%	233	6%	208	5%
2014	511	7%	238	6%	271	7%
2015	574	7%	305	8%	267	7%
2016	648	8%	323	9%	323	8%
2017	874	11%	408	11%	466	12%
2018	1,098	14%	553	15%	545	14%
2019	1,128	15%	539	14%	585	15%
2020	1,343	18%	676	18%	664	17%



**FIGURE 1.** Estimated associations of local bans on storefront recreational retail cannabis businesses with rates of harmful cannabis exposures reported to the California Poison Control System, 2011–2020.


and we restricted analyses to the 167 localities without retail bans by 2021. Thus, estimates were imprecise. There was some indication that localities adopting packaging and labeling requirements by 2021 experienced fewer harmful cannabis exposures among people aged 13 years and older, specifically for male patients ( $RR = 0.76$ ; 95%  $CI = 0.60, 0.97$ ) and calls originating from the community ( $RR = 0.70$ ; 95%  $CI = 0.58, 0.83$ ). Server training requirements were also unexpectedly associated with more harmful cannabis exposures among people aged 13 years and older ( $RR = 1.23$ ; 95%  $CI = 1.01, 1.51$ ).

Results from sensitivity analyses including cases of unknown severity were consistent with the main results (eFigures 5–9; <http://links.lww.com/EDE/C129>).

DISCUSSION

In this statewide retrospective study of all 539 California localities (cities and counties), the restrictiveness of local cannabis control policies adopted by 2021 was associated with differential rates of harmful cannabis exposures

reported to the CPCS following before versus after state-wide cannabis commercialization in 2018. Local bans on storefront recreational retail cannabis businesses by 2021 were associated with 18% fewer harmful cannabis exposures among children under 13 years, but no difference in harmful cannabis exposures among people aged 13 years and older. Among the 167 localities without retail bans, more restrictive local approaches to cannabis control by 2021 were associated with fewer harmful cannabis exposures for people aged 13 years and older, specifically for medium-severity cases and calls originating from health care facilities. We also examined specific cannabis control provisions proposed as solutions to harmful cannabis exposures: limits on product types and potency, packaging and labeling requirements, and server training requirements.<sup>9</sup> However, we found that these policies were rarely adopted by 2021 and corresponding estimates were generally too imprecise to determine their effectiveness. Overall, these findings are important for informing local governments’ approaches to prevent harmful cannabis exposures,



**FIGURE 2.** Estimated associations of overall restrictiveness of locality cannabis control policies with rates of harmful cannabis exposures reported to the California Poison Control System, 2011–2020. Estimates correspond to the change in the rate of harmful cannabis exposures associated with a 1-standard deviation (SD) increase in the policy restrictiveness score.

because they suggest that taking more restrictive approaches to local cannabis control may help mitigate some increases in harmful cannabis exposures following statewide recreational cannabis commercialization.

Increases in harmful cannabis exposures reported after commercialization may reflect a greater willingness to call Poison Control after penalties for possession and use were lifted for adults aged 21 and older.<sup>19,20</sup> This may have been especially true in localities that permitted local retail, whereas calls may have increased less in places with retail bans. However, this reporting bias cannot explain all the findings because we observed increases in harmful cannabis exposures after commercialization when recreational cannabis use had already been decriminalized for several years. Additionally, the changes we observed occurred primarily for calls originating from health care providers, whose propensity to call Poison Control is unlikely to be affected by cannabis laws.

Local cannabis control policies designed to reduce the availability and demand for recreational cannabis, including retail bans, may contribute to lower levels of cannabis use and corresponding problems. In particular, changes in rates of harmful cannabis exposures may reflect differential availability, purchasing, and use of cannabis products, particularly high-potency and edible products that may be less familiar to users. In most states legalizing recreational cannabis, cannabis use increased among adults,<sup>46</sup> and edibles increased in popularity.<sup>47</sup> Potency of cannabis products also increased.<sup>5,6</sup> In California, the proportion of cannabis-related CPCS calls attributable to chocolates, candies, gummies, and other edibles increased dramatically following statewide legalization.<sup>20</sup> When recreational cannabis sales began in 2018, many localities introduced recreational cannabis retail outlets by converting existing medical cannabis dispensaries; these outlets were therefore poised to distribute diverse high-potency cannabis products.<sup>48,49</sup> Lower availability of these products, in places



with retail bans and in places that permitted businesses but regulated them, may have resulted in fewer harmful cannabis exposures relative to localities with less restrictive policies.

We cannot rule out the possibility of uncontrolled confounding or reverse causation. Localities adopting more cannabis control policies may be those with larger cannabis markets. Restrictive policies may also be adopted in response to more frequent problems (i.e., reverse causation), consistent with prior work showing that restrictions on outlet overconcentration in historically disinvested neighborhoods were more common in California localities with such problems.<sup>35</sup> In future studies, longitudinal policy measures would help rule out reverse causation. Additionally, not all localities have the capacity or expertise to develop nuanced cannabis control regulations; more restrictive or complex policies may reflect the greater capacity of larger localities, which are also more likely to experience a harmful cannabis exposure because the population is larger. The ongoing presence of a widespread illegal cannabis market<sup>50</sup> and misalignment between the frequency of cannabis use and cannabis use problems may also contribute to variation in our findings.

Lower rates of harmful cannabis exposures associated with more restrictive cannabis control policies were driven primarily by medium-severity cases (defined as non-life-threatening cases needing medical attention). The policies we studied may therefore be more relevant for cannabis exposures serious enough to require medical attention. While minor cases are a nuisance, they are unlikely to be a major threat to population health. In contrast, preventing serious cannabis-related harm is a public policy imperative. Our findings suggest that retail bans and more restrictive overall approaches to local cannabis control may help prevent some of these cases (medium severity).

Consistent with prior research,<sup>20</sup> our findings differed for children aged 12 and under compared with people aged 13 and older. Local retail bans were associated with fewer harmful cannabis exposures for children aged 12 and under, whereas more restrictive overall approaches to local cannabis control among localities permitting retail were associated with fewer harmful cannabis exposures for people aged 13 years and older. If these associations are causal, they suggest that banning recreational cannabis retail altogether is more likely to be effective in preventing harmful cannabis exposures among children, whereas for the older age group, permitting but constraining recreational cannabis retail may be sufficient. Harmful cannabis exposures among children typically involve unintentional ingestion of edibles, whereas harmful cannabis exposures among adults more often involve intentional consumption of various products.<sup>20</sup> Prevention strategies may need to be tailored to the type of product (e.g., ingested versus inhaled) and the nature of the exposure (i.e., intentional versus unintentional). For example, prevention of child exposures may be centered around child supervision or safe storage practices.<sup>26</sup>

## Strengths and Limitations

This study has several notable strengths, including the comprehensive collection of local cannabis control policy data, examination of specific provisions as opposed to legalization or commercialization alone, restriction to calls involving actual health harms, and use of locality and time-fixed effects to control for time-constant characteristics of localities (e.g., political orientation, population density, and wealth) and place-invariant temporal patterns (e.g., statewide recreational cannabis legalization, statewide secular trends in cannabis product potency, secular trends in population propensity to call Poison Control).

Research using Poison Control records has strengths and limitations. Poison Control records capture incidents both inside and outside the health system (particularly given that calling is costless to callers), are widely used in research, and are complementary to population-based surveys and health care utilization records. However, Poison Control is a passive surveillance system relying on voluntary reporting. It captures a nonrandom sample of all harmful cannabis exposures. As health care providers become more comfortable managing pediatric marijuana intoxication, they may call CPCS less frequently. Nationally, Poison Control records capture an estimated half of all exposures,<sup>51</sup> but this proportion could be lower for harmful cannabis exposures. If the probability that incidents are captured in CPCS records is associated with local cannabis control policies, this could lead to selection bias in an unknown direction. Additionally, we were unable to distinguish cannabis exposures arising from legal versus illicit sources or hemp-derived products.

We assessed local policies cross-sectionally at the end of the study period, though local cannabis control policies evolved since legalization. Thus, some local policies may be misclassified (see eAppendix 3; <http://links.lww.com/EDE/C129>). Like most studies of public policies, the policy exposures were not randomized and residual confounding is possible. Potential unmeasured confounders include community-based prevention campaigns. However, there was substantial variation in local approaches to cannabis control across California's 539 localities, and localities with similar characteristics frequently adopted differing policies (i.e., like-random variation). Additionally, the locality where a harmful cannabis exposure occurred may not correspond to the locality where the cannabis was acquired. Some estimates were imprecise, making the findings less robust to the other limitations cited. In particular, our analyses had insufficient precision to fully detect differences in trends in harmful cannabis exposures between localities with and without specific recommended provisions. Because these policies were rare, we grouped heterogeneous policies. For example, limits on product types and potency included bans on cannabis-infused beverages and bans on edible products requiring refrigeration. Poor enforcement and easy travel across localities may compromise policy effectiveness.

Localities may also have limited influence given that many features of the legal cannabis market are set at the state level. California still has a robust illicit cannabis market, and we could not distinguish cannabis exposures associated with legally purchased products from those arising from illegal purchases. Finally, the California setting is unique, limiting generalizability.

## CONCLUSION

A growing number of US states now permit large-scale commercial markets for legal cannabis products. To ensure that the benefits of cannabis legalization exceed unintended harms, regulating agencies must establish policies to prevent cannabis-related problems identified in Poison Control records. We found that some harmful cannabis exposures were less frequent in 2018–2020 in localities banning or constraining storefront recreational retail cannabis sales by 2021, consistent with the hypothesis that these policies may help prevent the steep increases in harmful cannabis exposures that have been observed in states commercializing recreational cannabis.<sup>19–22</sup> Harmful cannabis exposures are preventable, burden the health system, and may have unequal impacts.<sup>31</sup> Our findings suggest that communities respond to local cannabis policies. Further research is needed on whether specific provisions regulating product types or potency, packaging and labeling, server training requirements, and other as-yet untested provisions can prevent harmful cannabis exposures, and to confirm whether the policy associations we identified hold for other relevant health-related outcomes including perceptions of harm, cannabis use initiation, and cannabis use disorder, and how these impacts vary across population subgroups.

## ACKNOWLEDGMENTS

The authors thank Sue Thomas, Ryan Treffers, Cynthia Fu, Catherine Mueller, Laura Rambaran, and Serena Zhang for their guidance, legal expertise, and contributions to collecting and coding the cannabis policy data.

## REFERENCES

- Hall W, Stjepanović D, Caulkins J, et al. Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. *Lancet*. 2019;394:1580–1590.
- Hall W, Lynskey M. Assessing the public health impacts of legalizing recreational cannabis use: the US experience. *World Psychiatry*. 2020;19:179–186.
- Barry RA, Glantz S. A public health framework for legalized retail marijuana based on the US experience: avoiding a new tobacco industry. *PLoS Med*. 2016;13:e1002131.
- Shover CL, Humphreys K. Six policy lessons relevant to cannabis legalization. *Am J Drug Alcohol Abuse*. 2019;45:698–706.
- Cascini F, Aiello C, Di Tanna G. Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. *Curr Drug Abuse Rev*. 2012;5:32–40.
- Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA. New trends in cannabis potency in USA and Europe during the last decade (2008–2017). *Eur Arch Psychiatry Clin Neurosci*. 2019;269:5–15.
- Hall W, Leung J, Carlini BH. How should policymakers regulate the tetrahydrocannabinol content of cannabis products in a legal market? *Addiction*. 2023;118:998–1003.
- PRSC Cannabis Concentration Workgroup. *Cannabis Concentration and Health Risks: A Report for the Washington State Prevention Research Subcommittee (PRSC)*. University of Washington. 2020. Available at: <https://adaa.uw.edu/wordpress/wp-content/uploads/2020/11/Cannabis-Concentration-and-Health-Risks-2020.pdf>. Accessed 2 October 2023.
- Matheson J, Le Foll B. Cannabis legalization and acute harm from high potency cannabis products: a narrative review and recommendations for public health. *Front Psychiatry*. 2020;11:591979.
- Spindle TR, Bonn-Miller MO, Vandrey R. Changing landscape of cannabis: novel products, formulations, and methods of administration. *Curr Opin Psychol*. 2019;30:98–102.
- Goodman S, Wadsworth E, Leos-Toro C, Hammond D; International Cannabis Policy Study team. Prevalence and forms of cannabis use in legal vs. illegal recreational cannabis markets. *Int J Drug Policy*. 2020;76:102658.
- Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid-related illnesses and deaths. *N Engl J Med*. 2015;373:103–107.
- United States Food and Drug Administration. *FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)*. 18 October 2021. Available at: <https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd>. Accessed 28 October 2022.
- Zupan Mežnar A, Brvar M, Kralj G, Kovačič D. Accidental cannabis poisoning in the elderly. *Wien Klin Wochenschr*. 2016;128:548–552.
- Gummin DD, Mowry JB, Beuhler MC, et al. 2020 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th annual report. *Clin Toxicol*. 2021;59:1282–1501.
- Hammond D. Communicating THC levels and 'dose' to consumers: implications for product labelling and packaging of cannabis products in regulated markets. *Int J Drug Policy*. 2021;91:102509.
- Wang GS, Le Lait MC, Deakyn SJ, Bronstein AC, Bajaj L, Roosevelt G. Unintentional pediatric exposures to marijuana in Colorado, 2009–2015. *JAMA Pediatr*. 2016;170:e160971.
- Tweet MS, Nemanich A, Wahl M. Pediatric edible cannabis exposures and acute toxicity: 2017–2021. *Pediatrics*. 2023;151:e2022057761.
- Shi Y, Liang D. The association between recreational cannabis commercialization and cannabis exposures reported to the US national poison data system. *Addiction*. 2020;115:1890–1899.
- Roth W, Tam M, Bi C, et al. Changes in California cannabis exposures following recreational legalization and the COVID-19 pandemic. *Clin Toxicol*. 2022;60:632–638.
- Yeung MEM, Weaver CG, Janz K, Haines-Saah R, Lang E. Clearing the air: a study of cannabis-related presentations to urban Alberta emergency departments following legalization. *CJEM*. 2020;22:776–783.
- Dilley JA, Graves JM, Brooks-Russell A, Whitehill JM, Liebelt EL. Trends and characteristics of manufactured cannabis product and cannabis plant product exposures reported to US Poison Control centers, 2017–2019. *JAMA Netw Open*. 2021;4:e2110925.
- Champagne AS, McFaul SR, Thompson W, Bang F. Original quantitative research - surveillance from the high ground: sentinel surveillance of injuries and poisonings associated with cannabis. *Health Promot Chronic Dis Prev Can*. 2020;40:184–192.
- Roberts BA. Legalized cannabis in Colorado emergency departments: a cautionary review of negative health and safety effects. *West J Emerg Med*. 2019;20:557–572.
- Ghosh TS, Vigil DI, Maffey A, et al. Lessons learned after three years of legalized, recreational marijuana: the Colorado experience. *Prev Med*. 2017;104:4–6.
- Van Oyen A, Perlman E, Su MK. The continued rise of unintentional ingestion of edible cannabis in toddlers—a growing public health concern. *JAMA Pediatrics*. 2022;176:1068–1069.
- Ghosh TS, Van Dyke M, Maffey A, Whitley E, Erpelding D, Wolk L. Medical marijuana's public health lessons—implications for retail marijuana in Colorado. *N Engl J Med*. 2015;372:991–993.
- Silver LD, Naprawa AZ, Padon AA. Assessment of incorporation of lessons from tobacco control in city and county laws regulating legal marijuana in California. *JAMA Netw Open*. 2020;3:e208393.

29. Dilley JA, Hitchcock L, McGroder N, Greto LA, Richardson SM. Community-level policy responses to state marijuana legalization in Washington State. *Int J Drug Policy*. 2017;42:102–108.
30. Payán DD, Brown P, Song AV. County-level recreational marijuana policies and local policy changes in Colorado and Washington State (2012–2019). *Milbank Q*. 2021;99:1132–1161.
31. Matthay EC, Mousli LM, Fu C, et al. Equity in coverage of local cannabis control policies in California, 2020–2021. *Am J Public Health*. 2022;112:1640–1650.
32. Alcohol Policy Information System. *Recreational Use of Cannabis: Volume 1*. National Institute of Alcohol Abuse and Alcoholism. 2022. Available at: <https://alcoholpolicy.niaaa.nih.gov/cannabis-policy-topics/recreational-use-of-cannabis-volume-1/104>. Accessed 2 May 2023.
33. *In California, the World's Largest Legal Weed Market Is Going Up in Smoke*. The Economist. 14 May 2022. Available at: <https://www.economist.com/united-states/2022/05/14/in-california-the-worlds-largest-legal-weed-market-is-going-up-in-smoke>. Accessed 3 January 2024.
34. Long A. *How Big is California's Legal Marijuana Market? Think a Small Nation*. MJBizDaily. 27 June 2023. Available at: <https://mjbizdaily.com/how-big-is-california-legal-marijuana-market/>. Accessed 3 January 2024.
35. Matthay EC, Mousli L, Ponicki WR, et al. A spatiotemporal analysis of the association of California city and county cannabis policies with cannabis outlet densities. *Epidemiology*. 2022;33:715–725.
36. Matthay EC, Mousli LM, Apollonio DE, Schmidt LA. Alignment in local approaches to alcohol and cannabis control policy: a case study of California cities and counties. *Int J Drug Policy*. 2023;119:104114.
37. Tremper C, Thomas S, Wagenaar A. Measuring the law for evaluation research. *Eval Rev*. 2010;34:242–266.
38. National Institute on Alcohol Abuse and Alcoholism. *How to Measure Law for Quantitative Research: A Resource Guide*. Available at: <https://alcoholpolicy.niaaa.nih.gov/resource/how-to-measure-law-for-quantitative-research-a-resource-guide/18>. Accessed 31 August 2021.
39. Klitzner MD, Thomas S, Schuler J, Hilton M, Mosher J. The new cannabis policy taxonomy on APIS: making sense of the cannabis policy universe. *J Prim Prev*. 2017;38:295–314.
40. Gruenewald PJ. Regulating availability: how access to alcohol affects drinking and problems in youth and adults. *Alcohol Res Health*. 2011;34:248–256.
41. Roth J, Sant'Anna PHC, Bilinski A, Poe J. What's trending in difference-in-differences? A synthesis of the recent econometrics literature. *J Econom*. 2023;235(2):2218–2244.
42. Schell TL, Griffin BA, Morral AR. *Evaluating Methods to Estimate the Effect of State Laws on Firearm Deaths: A Simulation Study*. RAND Corporation. 2018. Available at: <https://doi.org/10.7249/RR2685>. Accessed 13 December 2022.
43. Angrist JD, Pischke J. Parallel worlds: fixed effects, differences-in-differences, and panel data. In: *Mostly Harmless Econometrics: An Empiricist's Companion*. Princeton University Press; 2009:221–248.
44. Rothman KJ. No adjustments are needed for multiple comparisons. *Epidemiology*. 1990;1:43–46.
45. Lash TL. The harm done to reproducibility by the culture of null hypothesis significance testing. *Am J Epidemiol*. 2017;186:627–635.
46. Smart R, Pacula RL. Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: findings from state policy evaluations. *Am J Drug Alcohol Abuse*. 2019;45:644–663.
47. Eaze Insights. *State of Cannabis 2020*. Eaze Cannabis Delivery. 27 January 2021. Available at: <https://www.eaze.com/article/state-of-cannabis-2020>. Accessed 28 October 2022.
48. Freisthler B, Gaidus A, Tam C, Ponicki WR, Gruenewald PJ. From medical to recreational marijuana sales: marijuana outlets and crime in an era of changing marijuana legislation. *J Prim Prev*. 2017;38:249–263.
49. Pedersen ER, Firth C, Parker J, et al. Locating medical and recreational cannabis outlets for research purposes: online methods and observational study. *J Med Internet Res*. 2020;22:e16853.
50. Unger JB, Vos RO, Wu JS, et al. Locations of licensed and unlicensed cannabis retailers in California: a threat to health equity? *Prev Med Rep*. 2020;19:101165.
51. Institute of Medicine. *Forging a Poison Prevention and Control System*. National Academies Press; 2004.